Editorial: Seton Use in Perianal Fistulising Crohn's Disease
- PMID: 40289273
- DOI: 10.1111/apt.70094
Editorial: Seton Use in Perianal Fistulising Crohn's Disease
References
-
- S. Glaser, “Hippocrates and Proctology,” Proceedings of the Royal Society of Medicine 62, no. 4 (1969): 380–381, https://doi.org/10.1177/003591576906200437.
-
- J. Geldof, N. Iqbal, J. F. LeBlanc, et al., “Classifying Perianal Fistulising Crohn's Disease: An Expert Consensus to Guide Decision‐Making in Daily Practice and Clinical Trials,” Lancet Gastroenterology & Hepatology 7, no. 6 (2022): 576–584, https://doi.org/10.1016/S2468‐1253(22)00007‐3.
-
- L. N. Hanna, S. Anandabaskaran, N. Iqbal, et al., “Perianal Fistulizing Crohn's Disease: Utilizing the TOpClass Classification in Clinical Practice to Provide Targeted Individualized Care,” Clinical Gastroenterology and Hepatology (2024), https://doi.org/10.1016/j.cgh.2024.06.047. Epub ahead of print.
-
- E. Anand, T. Pelly, S. Joshi, et al., “Current Practice and Innovations in Diagnosing Perianal Fistulizing Crohn's Disease (pfCD): A Narrative Review,” Techniques in Coloproctology (2025), https://doi.org/10.1007/s10151‐025‐03122‐6.
-
- J. McCurdy, J. Munir, S. Parlow, et al., “The Impact of Setons on Perianal Fistula Outcomes in Patients With Crohn's Disease Treated With Anti‐TNF Therapy: A Multicentre Study,” Alimentary Pharmacology & Therapeutics 61, no. 10 (2025): 1671–1679, https://doi.org/10.1111/apt.70081.